Genetic variants involved in innate immunity modulate the risk of inflammatory bowel diseases in an understudied Malaysian population

2021 ◽  
Author(s):  
Laurence Don Wai Luu ◽  
Georgia Popple ◽  
Samuel Pok Wei Tsang ◽  
Karla Vinasco ◽  
Ida Hilmi ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Malaysian Population ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Innate Immunity Modulation by the IL-33/ST2 System in Intestinal Mucosa

2013 ◽  
Vol 2013 ◽  
pp. 1-13 ◽  
Author(s):  
Marina García-Miguel ◽  
M. Julieta González ◽  
Rodrigo Quera ◽  
Marcela A. Hermoso
Keyword(s):  
Ulcerative Colitis ◽  
Innate Immunity ◽  
Intestinal Mucosa ◽  
Inflammatory Bowel Diseases ◽  
The Body ◽  
Unknown Etiology ◽  
Adequate Food ◽  
Bowel Diseases ◽  
Surface Contact Area ◽  
Inflammatory Bowel

Innate immunity prevents pathogens from entering and spreading within the body. This function is especially important in the gastrointestinal tract and skin, as these organs have a large surface contact area with the outside environment. In the intestine, luminal commensal bacteria are necessary for adequate food digestion and play a crucial role in tolerance to benign antigens. Immune system damage can create an intestinal inflammatory response, leading to chronic disease including inflammatory bowel diseases (IBD). Ulcerative colitis (UC) is an IBD of unknown etiology with increasing worldwide prevalence. In the intestinal mucosa of UC patients, there is an imbalance in the IL-33/ST2 axis, an important modulator of the innate immune response. This paper reviews the role of the IL-33/ST2 system in innate immunity of the intestinal mucosa and its importance in inflammatory bowel diseases, especially ulcerative colitis.

Innate immunity and paediatric onset inflammatory bowel diseases: A human beta defensins genotype investigation

2007 ◽  
Vol 39 (10) ◽  
pp. A50-A51
Author(s):  
M.C. Siani ◽  
O. Scudiero ◽  
S. Cucchiara ◽  
E. Romeo ◽  
G. De Angelis ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Beta Defensins

scholarly journals Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases

2015 ◽  
Vol 21 (11) ◽  
pp. 2507-2514 ◽  
Author(s):  
Ashwin N. Ananthakrishnan ◽  
Andrew Cagan ◽  
Tianxi Cai ◽  
Vivian S. Gainer ◽  
Stanley Y. Shaw ◽  
...  
Keyword(s):  
Vitamin D ◽  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Common Genetic Variants ◽  
Vitamin D Levels ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Reduced Thioredoxin-1 (TRX) Expression Might Compromise Luminal Innate Immunity in Colonic Inflammatory Bowel Diseases

2011 ◽  
Vol 140 (5) ◽  
pp. S-495-S-496
Author(s):  
Simon Jaeger ◽  
Julia Beisner ◽  
Bjoern Schroeder ◽  
Michael Gersemann ◽  
Eduard Stange ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Thioredoxin 1 ◽  
Inflammatory Bowel

Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases

2013 ◽  
Vol 45 (12) ◽  
pp. 1003-1010 ◽  
Author(s):  
Francesca Tavano ◽  
Orazio Palmieri ◽  
Fabio Francesco di Mola ◽  
Anna Latiano ◽  
Francesca Paola Burbaci ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals A Spectrum of Genetic Variants Contributes to Immune Defects and Pathogenesis of Inflammatory Bowel Diseases

2018 ◽  
Vol 154 (8) ◽  
pp. 2022-2024 ◽  
Author(s):  
Holm H. Uhlig ◽  
Claire Booth
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Immune Defects

Associations Between Genetic Variants in the IRGM Gene and Inflammatory Bowel Diseases in the Korean Population

2013 ◽  
Vol 19 (1) ◽  
pp. 106-114 ◽  
Author(s):  
Chang Mo Moon ◽  
Dong-Jik Shin ◽  
Seung Won Kim ◽  
Nak-Hoon Son ◽  
Ahram Park ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Korean Population ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Genetic variants in the IL12B gene are associated with inflammatory bowel diseases in the K orean population

2013 ◽  
Vol 28 (10) ◽  
pp. 1588-1594 ◽  
Author(s):  
Chang Mo Moon ◽  
Dong‐Jik Shin ◽  
Nak‐Hoon Son ◽  
Eun‐Soon Shin ◽  
Sung Pil Hong ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Il12b Gene

scholarly journals P830 Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S643-S644
Author(s):  
J Y Chang ◽  
S J Park ◽  
E S Jung ◽  
S A Jung ◽  
C M Moon ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Variants ◽  
Controlled Study ◽  
Drug Discontinuation ◽  
Genotype Analysis ◽  
Cell Counts ◽  
Thiopurine Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Pre Treatment

Abstract Background Thiopurine-related myelosuppression (most frequently leukopenia) interferes with thiopurine therapy for patients with inflammatory bowel diseases (IBD). We investigated whether pre-treatment analyses genetic variants associated with thiopurine-induced leukopenia could be used to effectively identify patients who required dose adjustments. Methods We performed a multicentre, prospective study of patients with IBD at 5 tertiary medical centres in Korea, from January 2016 through September 2018. Seventy-two patients were randomly assigned to a group that underwent genotype analysis for the NUDT15 variant (rs116855232) and FTO variant (rs79206939) and 3 common TPMT variants (rs1800460, rs1800462, rs1142345) associated with myelosuppression and 92 patients were assigned to a group that did not undergo genotype analysis (non-genotyping group). Patients heterozygous for any variant received 50 mg azathioprine equivalents, whereas those who were homozygous for any variant received alternative drugs. Patients who did not carry any of the genetic variants and patients in the non-genotyping group received 50 mg azathioprine equivalents followed by dose escalation up to 2–2.5 mg/kg. Myelosuppression was defined as white blood cell counts below 3000/μL, levels of haemoglobin 10 g/dl, or platelet counts below 100 K/μl. Results Twelve patients (16.7%) in the genotype analysis group and 33 patients (35.9%) in the non-genotyping group developed myelosuppression (p = .005). A multivariate analysis revealed that body mass indices above 21 kg/m2 (hazard ratio [HR], 0.43; 95% CI, 0.22–0.81; p = 0.009), pre-treatment genotype analysis (HR, 0.37; 95% CI, 0.18–0.77; p = 0.008), and the maximum dose of thiopurines (HR, 0.34; 95% CI, 0.19–0.59; p < 0.001) independently decreased risk of myelosuppression. Pre-treatment genotype analysis reduced numbers of outpatient clinic visit and numbers of patients with drug discontinuation or dose reductions. Conclusion In a randomised controlled study of patients undergoing thiopurine therapy for IBD, we found that selection of therapy based on genetic variants associated with thiopurine-induced leucopoenia significantly reduced the proportion of patients with myelosuppression during treatment.

Sign in / Sign up

Export Citation Format

Share Document